Clinical Trial of PCV13 in Infants Aged Approximately 2 Months (42 to 89 Days)
A Phase III, Randomized, Double-blind, Active Controlled Clinical Trial to Evaluate the Immunogenicity and Safety of a 13-valent Pneumococcal Polysaccharide Conjugate Vaccine Administered as a Series of 2 Infant Doses and 1 Toddler Dose in Healthy Infants
A Phase III clinical trial of 13-valent pneumococcal conjugate vaccine (PCV13)developed by Sinovac Life Science Co., Ltd will be conducted in infants aged approximately 2 months (42 to 89 days).
The objective of the study is to evaluate the immunogenicity and safety of Sinovac PCV13. The trial is a randomized, double-blind, active controlled phase III clinical trial.
調査の概要
詳細な説明
A phase III clinical trial of the study of 13-valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) developed by Sinovac Life Science Co., Ltd (Sinovac) will be conducted in Philippines infants aged approximately 2 months (42 to 89 days).
The trial is a randomized, double-blind, active controlled study. The objective of this study is to evaluate the immunogenicity and safety of PCV13 manufactured by Sinovac Life Science Co., Ltd. The active control vaccine is Prevenar 13™ manufactured by Pfizer.
About 500 infants aged approximately 2 months (42 to 89 days) will be enrolled. Participants will be randomized in 1:1 ratio to the test group and control group.
研究の種類
入学 (推定)
段階
- フェーズ 3
連絡先と場所
研究連絡先
- 名前:Edison Alberto
- 電話番号:(046)471-0996/+639171490841
- メール:edisonalberto@rocketmail.com
研究場所
-
-
Cavite
-
Imus、Cavite、フィリピン
- Health Index Multispecialty Clinic (HIMC) Research and Development on Medical Sciences
-
コンタクト:
- Edison R. Alberto
- 電話番号:(046)471-0996/+639171490841
- メール:edisonalberto@rocketmail.com
-
-
参加基準
適格基準
就学可能な年齢
- 子
健康ボランティアの受け入れ
説明
Inclusion Criteria:
- Health infants aged approximately 2 months (42 to 89 days)
- Have a parent/legal guardian who has provided written informed consent after being fully informed about the study.
- Be able to provide the vaccination records since birth.
- The infant's mother is tested negative for HIV, syphilis, hepatitis B, and hepatitis C before the infant's enrollment to this study (test results obtained during pregnancy are acceptable, if provided).
Exclusion Criteria:
- Previous vaccination of any licensed or investigational pneumococcal vaccine, or planned receipt during the study participation;
- Previous vaccination of vaccines containing the component of diphtheria, tetanus, pertussis, poliomyelitis, and/or Hib vaccine.
- Previous receipt of ≥2 doses of hepatitis B vaccine; or receipt of a single hepatitis B vaccine dose administered at >30 days old.
- History of severe adverse reaction to previous vaccinations and/or serious allergic reactions (eg, anaphylaxis) to any vaccine component.
- History of any laboratory confirmed pneumococcal bacterial pneumonia or invasive pneumococcal diseases caused by S pneumoniae.
- Premature infants (born before week 37 of gestation).
- Severe congenital malformations, developmental disorders, clinically significant genetic defects, malnutrition.
- Autoimmune diseases or immunodeficiency/immunosuppression.
- Serious chronic diseases such as Down's syndrome, diabetes, sickle cell anemia, or neurological disorders.
- Abnormal coagulation functions (e.g., coagulation factor deficiency, blood coagulation diseases, platelet disorders).
- Received immunosuppressive for ≥14 days (e.g., prednisone equivalent of ≥2 mg/kg), or cytotoxic drug before enrollment, or plans to receive these treatments during the study participation.
- Received blood products before investigational vaccine inoculation, or plan to receive these treatments during study participation.
- Received other investigational drugs/vaccines before enrollment, or plan to receive investigational drugs/vaccines during study participation.
- Received live attenuated vaccines or nucleic-acid vaccines within 14 days before enrollment.
- Received subunit or inactivated vaccines within 7 days before enrollment.
- Acute diseases or acute exacerbations of chronic diseases within 7 days before enrollment.
- Axillary temperature ≥ 37.5°C before enrollment.
- Any other factors judged by the investigators as unsuitable for participation.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:防止
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:4倍
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Sinovac PCV 13
250 participants aged 2 months (42 to 89 days) will receive 3 doses of Sinovac PCV13 at approximately 2, 4 and 12-15 months of age.Route of administration is intramuscular injection at anterolateral thigh for infants aged younger than 12 months, and at deltoid muscle of upper arm for children aged older than 12 months.
|
One dose of Sinovac PCV13 (0.5ml) was administered at 2, 4, and 12-15 months of age.
|
|
アクティブコンパレータ:Prevenar 13™
250 participants aged 2 months (42 to 89 days) will receive 3 doses of Prevenar 13™ at approximately 2, 4 and 12-15 months of age.Route of administration is intramuscular injection at anterolateral thigh for infants aged younger than 12 months, and at deltoid muscle of upper arm for children aged older than 12 months.
|
One dose of Prevenar 13™ (0.5ml) was administered at 2, 4, and 12-15 months of age.
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Percentage of participants with pneumococcal serotype-specific IgG antibody concentrations≥0.35 μg/mL .
時間枠:30 days after dose 2.
|
Non-inferiority criterion: The lower limit of the two-sided 95% CI for the difference (Sinovac-PCV13 minus Prevenar 13™) > -10% for each serotype at 30 days after dose 2.
|
30 days after dose 2.
|
|
Geometric mean concentrations (GMCs) of serotype-specific IgG antibody.
時間枠:30 days after dose 2
|
Non-inferiority criterion: The lower limit of the two-sided 95% CI for the GMC ratio (Sinovac-PCV13/Prevenar 13™) > 0.5 for each serotype at 30 days after dose 2.
|
30 days after dose 2
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
副作用の発現状況
時間枠:各投与後0~7日
|
各投与後7日以内の副作用の発生率
|
各投与後0~7日
|
|
Percentage of participants with pneumococcal serotype-specific IgG antibody concentrations≥0.35 μg/mL .
時間枠:30 days after dose 3.
|
Non-inferiority criterion: The lower limit of the two-sided 95% CI for the difference (Sinovac-PCV13 minus Prevenar 13™) > -10% for each serotype at 30 days after dose 3.
|
30 days after dose 3.
|
|
Geometric mean concentrations (GMCs ) of serotype-specific IgG antibody.
時間枠:30 days after dose 3.
|
Non-inferiority criterion: The lower limit of the two-sided 95% CI for the GMC ratio (Sinovac-PCV13/Prevenar 13™) > 0.5 for each serotype at 30 days after dose 3.
|
30 days after dose 3.
|
|
Percentage of participants with serotype-specific IgG concentrations ≥ 1.0 μg/mL
時間枠:30 days after dose 2
|
Percentage of participants with serotype-specific IgG concentrations ≥ 1.0 μg/mL at 30 days after dose 2
|
30 days after dose 2
|
|
Percentage of participants with serotype-specific IgG concentrations ≥ 1.0 μg/mL .
時間枠:30 days after dose 3
|
Percentage of participants with serotype-specific IgG concentrations ≥ 1.0 μg/mL at 30 days after dose 3.
|
30 days after dose 3
|
|
GMC fold increases (GMFRs) in IgG antibody concentrations.
時間枠:From before dose 3 to 30 days after dose 3
|
GMC fold increases (GMFRs) in IgG antibody concentrations from before dose 3 to 30 days after dose 3.
|
From before dose 3 to 30 days after dose 3
|
|
Percentage of participants with serotype-specific opsonophagocytosis assay (OPA) antibody titers ≥1:8
時間枠:30 days after the dose 2.
|
Percentage of participants with serotype-specific OPA antibody titers ≥1:8 at 30 days after the dose 2.
|
30 days after the dose 2.
|
|
Percentage of participants with serotype-specific OPA antibody titers ≥1:8.
時間枠:30 days after the dose 3.
|
Percentage of participants with serotype-specific OPA antibody titers ≥1:8 at 30 days after the dose 3.
|
30 days after the dose 3.
|
|
Geometric mean titers (GMTs) of serotype-specific OPA antibody.
時間枠:30 days after dose 2.
|
Geometric mean titers (GMTs) of serotype-specific OPA antibody 30 days after dose 2.
|
30 days after dose 2.
|
|
GMTs of serotype-specific OPA antibody .
時間枠:30 days after dose 3.
|
GMTs of serotype-specific OPA antibody at 30 days after dose 3.
|
30 days after dose 3.
|
|
GMT fold rises (GMFRs) in OPA titers.
時間枠:From before dose 3 to 30 days after dose 3.
|
GMT fold rises (GMFRs) in OPA titers from before dose 3 to 30 days after dose 3.
|
From before dose 3 to 30 days after dose 3.
|
|
Incidence of adverse reactions
時間枠:0-30 days after each dose.
|
Incidence of adverse reactions within 30 days after each dose.
|
0-30 days after each dose.
|
|
Incidence of serious adverse events(SAEs)
時間枠:From dose 1 to 30 days after dose 3
|
Incidence of SAEs from dose 1 to 30 days after dose 3
|
From dose 1 to 30 days after dose 3
|
|
Percentage of infants with anti-diphtheria toxoid IgG concentrations ≥ 0.1 IU/mL
時間枠:30 days after dose 3 of DTwP-HepB-Hib
|
Percentage of infants with anti-diphtheria toxoid IgG concentrations ≥ 0.1 IU/mL at 30 days after dose 3 of DTwP-HepB-Hib
|
30 days after dose 3 of DTwP-HepB-Hib
|
|
Percentage of infants with anti-tetanus toxoid IgG concentrations ≥ 0.1 IU/mL
時間枠:30 days after dose 3 of DTwP-HepB-Hib
|
Percentage of infants with anti-tetanus toxoid IgG concentrations ≥ 0.1 IU/mL at 30 days after dose 3 of DTwP-HepB-Hib
|
30 days after dose 3 of DTwP-HepB-Hib
|
|
Percentage of participants achieving an anti-acellular pertussis (PT, FHA and PRN antigens) antibody concentration
時間枠:30 days after dose 3 of DTwP-HepB-Hib
|
Percentage of participants achieving an anti-acellular pertussis (PT, FHA and PRN antigens) antibody concentration ≥ the observed anti-pertussis antibody concentration achieved by 95% of Prevenar 13™ recipients at 30 days after dose 3 of DTwP-HepB-Hib
|
30 days after dose 3 of DTwP-HepB-Hib
|
|
Percentage of infants with anti-Haemophilus influenzae type b (PRP) IgG concentration≥0.15 µg/mL
時間枠:30 days after dose 3 of DTwP-HepB-Hib
|
Percentage of infants with anti-Haemophilus influenzae type b (PRP) IgG concentration≥0.15
µg/mL at 30 days after dose 3 of DTwP-HepB-Hib
|
30 days after dose 3 of DTwP-HepB-Hib
|
|
Percentage of infants with anti-Hepatitis B surface antigen (HBsAg) antibody concentrations≥10 mIU/mL
時間枠:30 days after dose 3 of DTwP-HepB-Hib
|
Percentage of infants with anti-Hepatitis B surface antigen (HBsAg) antibody concentrations≥10 mIU/mL at 30 days after dose 3 of DTwP-HepB-Hib
|
30 days after dose 3 of DTwP-HepB-Hib
|
|
Percentage of infants with anti-poliovirus types 1, 2 and 3 neutralizing antibody titers≥1:8
時間枠:30 days after dose 3 of IPV
|
Percentage of infants with anti-poliovirus types 1, 2 and 3 neutralizing antibody titers≥1:8 measured at 30 days after dose 3 of IPV
|
30 days after dose 3 of IPV
|
協力者と研究者
捜査官
- 主任研究者:Edison Alberto、Health Index Multispecialty Clinic (HIMC) Research and Development on Medical Sciences
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- PRO-PCV13-3003
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。